2024
Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original Research
2023
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Traore K, Taneja A, Gorshein E, Castro F, Derkach A, Martinez J, Serrano E, Lesokhin A, Ahlstrom J, Block T, Hydren J, Usmani S, Shah U. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population. Blood 2023, 142: 7363. DOI: 10.1182/blood-2023-186913.Peer-Reviewed Original ResearchBody mass indexPlasma cell disordersHigher HEI scoresFood frequency questionnaireGeneral US populationHEI scoresDietary patternsTotal fruit consumptionMultiple myelomaUS populationDietary interventionDietary guidelinesFruit consumptionCell disordersHealthy dietBlock Food Frequency QuestionnaireElevated body mass indexLower body mass indexCancer-specific mortalityLong-term outcomesHealthy Eating IndexNutrition Examination SurveyHealthy dietary habitsRole of nutritionOlder age groups“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational Materials
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic valueUse of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance
2017
Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis
John E, Gorshein E, Dayan M, Katz K, Malhotra U. Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis. The American Journal Of Gastroenterology 2017, 112: s901. DOI: 10.14309/00000434-201710001-01664.Peer-Reviewed Original Research
2016
Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?
Zelefsky M, Kollmeier M, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen G, Yamada Y. Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental? Radiotherapy And Oncology 2016, 121: 109-112. PMID: 27756494, PMCID: PMC5546832, DOI: 10.1016/j.radonc.2016.08.010.Peer-Reviewed Original ResearchConceptsDegenerative joint diseaseHip painPersistent hip painSevere hip painLocalized prostate cancerOnly variableProstate cancer patientsExternal beam radiotherapyHip revision surgerySalvage therapySevere painCancer patientsProstate cancerJoint diseaseLower incidenceBeam radiotherapyHip replacementConcurrent ADTMultivariate analysisPatientsRadiotherapyPainProstate radiotherapyIncidenceAmbulationA Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient
Ha K, Gorshein E, John E, Gharibo M. A Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient. The American Journal Of Gastroenterology 2016, 111: s667. DOI: 10.14309/00000434-201610001-01462.Peer-Reviewed Original Research
2015
The Case of Mistaken Identity: Entamoeba histolytica presenting as Community Acquired Pneumonia
Ha K, Gorshein E, Skole K. The Case of Mistaken Identity: Entamoeba histolytica presenting as Community Acquired Pneumonia. The American Journal Of Gastroenterology 2015, 110: s386. DOI: 10.14309/00000434-201510001-00894.Peer-Reviewed Original Research
2014
Probiotic Enteric Regimen for Easing the Complications of Transplant
Gorshein E, Ambrosy S, Budney S, Vivas J, Manago J, McGrath M, Tyno A, Strair R. Probiotic Enteric Regimen for Easing the Complications of Transplant. Blood 2014, 124: 5877. DOI: 10.1182/blood.v124.21.5877.5877.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantExtensive chronic GVHDChronic GVHDProbiotic Lactobacillus GGAcute GVHDStem cell transplantComplication of transplantRetrospective analysisCell transplantLactobacillus GGThree-month intervalsStage IIIStem cell transplant patientsPilot studyProphylaxis of GVHDPrimary end pointEvidence of diseaseRisk of GVHDCell transplant patientsMarrow Transplant RegistryEfficacy of probioticsAdministration of probioticsIntestinal GVHDHost diseaseClinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
Gorshein E, Klein P, Boolbol S, Shao T. Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. Clinical Breast Cancer 2014, 14: 309-314. PMID: 24703318, DOI: 10.1016/j.clbc.2014.02.007.Peer-Reviewed Original ResearchConceptsWorse RFSTN statusBreast cancerClinical significanceSmall node-negative breast cancersNode-negative breast cancer patientsSmall node-negative tumorsNode-negative breast cancerAggressive adjuvant therapyNode-negative tumorsTN breast cancerKaplan-Meier methodBreast cancer patientsTriple-negative statusAdjuvant chemotherapyAdjuvant therapyRFS ratesMedian ageReceptor statusTumor sizeCancer patientsTN tumorsPatientsService databaseMultivariate analysis
2013
Predictors of Post-Radiation Therapy Hip-Related Toxicity After Radiation Therapy for Prostate Cancer
Zelefsky M, Gorshein E, Pei X, Schecter M, Kollmeier M. Predictors of Post-Radiation Therapy Hip-Related Toxicity After Radiation Therapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s381. DOI: 10.1016/j.ijrobp.2013.06.1000.Peer-Reviewed Original Research
2011
Predictors of Serum Testosterone Normalization after Neoadjuvant and Concurrent Androgen Deprivation Therapy in Conjunction with Radiotherapy for Localized Prostate Cancer
Zelefsky M, Gorshein E, Pei X, Kollmeier M, Cox B, Yamada Y, Zhang Z. Predictors of Serum Testosterone Normalization after Neoadjuvant and Concurrent Androgen Deprivation Therapy in Conjunction with Radiotherapy for Localized Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s381. DOI: 10.1016/j.ijrobp.2011.06.606.Peer-Reviewed Original Research